PDCD1 and non-small cell lung carcinoma: The most commonly represented cancer types in this cohort were non-small cell lung cancer and melanoma (28.4% and 28.2%, respectively), and the majority (75.2%) of patients were prescribed programmed cell death protein 1 (PD-1)-targeting agents.